Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal

Inclusion Criteria: * Females or Males, 18 to 55 years of age (inclusive). * Fitzpatrick Skin Type I - VI. * Tattoos containing black/blue ink alone or in combination with other colors. No tribal, scarred, high-ink density, or highly colorful tattoos. * Target tattoos older than 1 year. * Must be able to read, understand and sign the Informed Consent Form. * Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions. * Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area starting 2 to 4 weeks before the treatment and/or every day for the duration of the study, including the follow-up period. * Willing to use hydroquinone approximately 4 weeks pre-treatment and post-treatment if required by Investigator. * Willingness to have digital photographs taken of the treated area. * Agree not to undergo any other procedure(s) for the tattoo removal during the study. * Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study. Exclusion Criteria: * Participation in a study of another device or drug within 6 months prior to enrollment or during the study. * History of allergic reaction to pigments following tattooing. * Presence of double tattoo in the treatment area or presence of tribal, scarred, high-ink density, or highly colorful single tattoos. * History of allergy to local anesthetics. * History of allergy to topical antibiotics. * History of malignant tumors in the target area. * Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles. * Pregnant and/or breastfeeding. * Having an infection, dermatitis or a rash in the treatment area. * Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension. * Suffering from coagulation disorders or taking prescription anticoagulation medications. * History of keloid scarring, hypertrophic scarring or of abnormal wound healing. * History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications. * History of vitiligo, eczema, or psoriasis. * History of connective tissue disease, such as systemic lupus erythematosus or scleroderma. * History of seizure disorders due to light. * Any use of medication that is known to increase sensitivity to light according to the Investigator's discretion. * History of herpes simplex and/or herpes zoster (shingles). * History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer. * History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. * Systemic use of corticosteroid within 12 months of study participation. * Use of oral isotretinoin within 12 months of study participation and topical use of isotretinoin within 6 months on the treated area. * Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus. * Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. * Current smoker or history of smoking within 6 months of study participation. * As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.